Journal Article Epublish 7 citations
PubMed: 36160358 DOI: 10.5114/aoms/152467
Perspective: repurposed drugs for COVID-19.
Arch Med Sci 18(5):1378-1391
Authors: Kesara Na-Bangchang, Supatra Porasuphatana, Juntra Karbwang
Affiliations
- Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University, Pathumthani, Thailand.
- Department of Pharmacognosy and Toxicology, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand.
Abstract
Introduction
The article aims to emphasize the necessity of proper research design, both scientifically and ethically, in order to provide good evidence for physicians to base their decisions on when prescribing drug treatment.
Methods
Research articles and guidelines related to therapy of COVID-19 were searched from the PubMed database.
Results
Only remdesivir and tocilizumab are medicines that have been approved by the US FDA's decision to approve their clinical use in moderate and severe COVID-19.
Conclusions
Favipiravir, ivermectin and andrographolide need further well-conducted research to confirm the efficacy and safety against COVID-19 at different stages.
MeSH
Ivermectin, Pharmaceutical Preparations, Azithromycin, Therapeutics, Research, Covid-19